IPO - ORAGENICS INC

Form Type: S-1/A

Filing Date: 2025-01-08

Corporate Action: Ipo

Type: New

Accession Number: 000149315225001268

Filing Summary: Oragenics, Inc. has filed a Pre-Effective Amendment No. 2 to Form S-1 registration statement with the SEC to offer a public offering of up to 15,151,515 units. Each unit consists of one share of common stock and one common warrant or one Pre-Funded Warrant and one common warrant. The maximum offering amount is expected to raise around $5 million at an assumed public offering price of $0.33 per unit. The filing also includes details about fees to the placement agent, Dawson James Securities, Inc., and associated costs of approximately $350,000 for the offering. The document discusses risks involving liquidity, regulatory compliance, and the current stage of the company as a smaller reporting company engaged in the research and development of nasal delivery pharmaceutical medications, specifically its lead product ONP-002. This product aims to treat mild traumatic brain injury and the document highlights the acquisition of Neurology Assets from Odyssey Health, expanding its product portfolio. The anticipated timeline for development phases of ONP-002 is also provided.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2024-12-31

Corporate Action: Ipo

Type: New

Accession Number: 000149315224052623

Filing Summary: Oragenics, Inc. is initiating a public offering of up to 15,151,515 units, where each unit consists of one share of common stock (or a pre-funded warrant) and one common warrant to purchase one share of common stock. The offering price is projected at $0.33 per unit based on the last reported sale price on December 13, 2024. Each common warrant will have an exercise price of $0.33 and will expire five years after issuance. There is a unique provision for purchasers whose ownership might exceed certain thresholds allowing them to purchase pre-funded warrants. The offering is facilitated by Dawson James Securities, Inc. as the placement agent, aligning with Oragenics' strategic direction following their recent acquisition of neurology assets from Odyssey Health, Inc. for $1,000,000 in cash and equity. This acquisition is aimed at advancing the development of ONP-002, a drug for treating mild traumatic brain injuries, which has completed Phase 1 trials. The offering may terminate by January 31, 2025, unless concluded earlier. The document stresses the risks associated with the investment, the lack of an active trading market for units, and further regulatory considerations that need to be met to convert newly created preferred stock into common shares, ensuring compliance with NYSE listing requirements.

Document Link: View Document